Finch Therapeutics Group (FNCH) Competitors $12.44 +0.02 (+0.12%) As of 08/7/2025 03:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock FNCH vs. SRZN, CELU, PMVP, BYSI, FBRX, CNTX, PYXS, IMMX, IGMS, and CRVOShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Surrozen (SRZN), Celularity (CELU), PMV Pharmaceuticals (PMVP), BeyondSpring (BYSI), Forte Biosciences (FBRX), Context Therapeutics (CNTX), Pyxis Oncology (PYXS), Immix Biopharma (IMMX), IGM Biosciences (IGMS), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. Its Competitors Surrozen Celularity PMV Pharmaceuticals BeyondSpring Forte Biosciences Context Therapeutics Pyxis Oncology Immix Biopharma IGM Biosciences CervoMed Finch Therapeutics Group (NASDAQ:FNCH) and Surrozen (NASDAQ:SRZN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings. Does the media favor FNCH or SRZN? In the previous week, Surrozen had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Surrozen and 0 mentions for Finch Therapeutics Group. Finch Therapeutics Group's average media sentiment score of 0.00 equaled Surrozen'saverage media sentiment score. Company Overall Sentiment Finch Therapeutics Group Neutral Surrozen Neutral Do analysts recommend FNCH or SRZN? Surrozen has a consensus target price of $38.50, indicating a potential upside of 326.36%. Given Surrozen's stronger consensus rating and higher probable upside, analysts plainly believe Surrozen is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Surrozen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, FNCH or SRZN? Finch Therapeutics Group has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Do institutionals & insiders believe in FNCH or SRZN? 21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 66.6% of Surrozen shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 45.2% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is FNCH or SRZN more profitable? Finch Therapeutics Group's return on equity of -69.14% beat Surrozen's return on equity.Company Net Margins Return on Equity Return on Assets Finch Therapeutics GroupN/A -69.14% -26.92% Surrozen N/A -842.90%-71.32% Which has better earnings & valuation, FNCH or SRZN? Surrozen has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.41Surrozen$11.64M6.64-$63.56M-$24.96-0.36 SummarySurrozen beats Finch Therapeutics Group on 9 of the 13 factors compared between the two stocks. Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.96M$283.63M$5.48B$9.57BDividend YieldN/AN/A3.99%4.17%P/E Ratio-1.41N/A29.9425.14Price / SalesN/A461.90398.9486.71Price / CashN/A22.4435.9458.58Price / Book0.879.538.105.59Net Income-$74.75M-$115.81M$3.26B$265.48M7 Day Performance-0.20%1.09%0.68%1.22%1 Month Performance-4.27%8.37%2.46%0.39%1 Year Performance197.73%-3.24%27.69%23.47% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics GroupN/A$12.45+0.1%N/A+288.9%$19.96MN/A-1.41190Gap DownSRZNSurrozen1.8253 of 5 stars$9.25-0.6%$38.50+316.2%+25.4%$79.72M$10.65M-0.3780News CoveragePositive NewsUpcoming EarningsGap UpCELUCelularity0.0723 of 5 stars$3.19-3.0%N/A+17.3%$78.79M$54.22M-1.20220PMVPPMV Pharmaceuticals2.979 of 5 stars$1.44-4.6%$5.50+281.9%-0.7%$78.45MN/A-1.2250News CoverageNegative NewsBYSIBeyondSpringN/A$2.01+4.7%N/A+13.3%$77.41M$1.75M0.0080Positive NewsFBRXForte Biosciences3.1266 of 5 stars$10.66-8.3%$61.00+472.2%+54,675.6%$76.57MN/A-0.655News CoveragePositive NewsUpcoming EarningsOptions VolumeGap UpCNTXContext Therapeutics2.8261 of 5 stars$0.83-2.4%$5.50+562.7%-70.1%$76.25MN/A-2.687News CoverageEarnings ReportAnalyst ForecastPYXSPyxis Oncology2.558 of 5 stars$1.14-6.9%$9.00+689.5%-65.8%$75.89MN/A-0.7260News CoverageUpcoming EarningsIMMXImmix Biopharma2.6523 of 5 stars$2.70-0.7%$7.00+159.3%+17.2%$75.83MN/A-3.869Upcoming EarningsIGMSIGM Biosciences4.4697 of 5 stars$1.26flat$5.50+336.5%-85.0%$75.75M$2.68M-0.39190Upcoming EarningsCRVOCervoMed2.8635 of 5 stars$8.42-2.9%$21.50+155.3%-17.6%$75.45M$9.74M-3.864Gap Up Related Companies and Tools Related Companies SRZN Alternatives CELU Alternatives PMVP Alternatives BYSI Alternatives FBRX Alternatives CNTX Alternatives PYXS Alternatives IMMX Alternatives IGMS Alternatives CRVO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FNCH) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FNCH Stock Alerts